enGene Holdings Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ENGN research report →
Range $3 – $6
Price Chart
About the company
Operating through its subsidiary, enGene, Inc. , enGene Holdings Inc. functions as a clinical-stage biotechnology firm.
- CEO
- Ronald H. W. Cooper
- IPO
- 2022
- Employees
- 82
- HQ
- Montreal, QC, CA
Get TickerSpark's AI analysis on ENGN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $116.61M
- P/E
- -6.41
- PEG
- -0.06
- P/S
- 0.00
- P/B
- 0.54
- EV/EBITDA
- -0.85
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -2.10%
- ROIC
- -1.61%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-123,165,000
- Net Income
- $-117,302,000-112.7%
- EPS
- $-2.29-56.8%
- OCF Growth
- -105.5%
- FCF Growth
- -104.7%
- 52W High
- $12.25
- 52W Low
- $1.40
- 50D MA
- $1.79
- 200D MA
- $3.79
- Beta
- -0.28
- RSI (14)
- 49
- Avg Volume
- 1.11M
No earnings-call transcripts are available for ENGN yet.
- Free Float
- 36.6%
- Shares Outstanding
- 67.02M
- Float Shares
- 24.52M
of shares held by institutions
66 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Fcpm Iii Services B.V. | 9.63M | 0 |
| Bml Capital Management, LLC | 6.67M | 0 |
| Siren, L.L.C. | 6.26M | 0 |
| Perceptive Advisors LLC | 4.82M | ▼ 1.01M |
| Eventide Asset Management, LLC | 3.41M | ▲ 3.41M |
| Ameriprise Financial Inc | 2.68M | ▲ 2.68M |
| Nextech Invest Ltd. | 2.32M | 0 |
| Adar1 Capital Management, LLC | 2.10M | ▲ 1.97M |
| Vestal Point Capital, LP | 1.67M | ▼ 497.57K |
| Acorn Capital Advisors, LLC | 1.27M | ▲ 1.27M |
| Renaissance Technologies LLC | 1.13M | ▲ 304.70K |
| Balyasny Asset Management L.P. | 1.01M | ▼ 141.65K |
Held by 2 ETFs
Biggest fund positions in ENGN by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 13, 26 | Duncan Jason | other | 500,000 |
| Nov 9, 26 | Duncan Jason | other | 0 |
| Sep 22, 26 | Grossman William | buy | 5,102 |
| Jul 16, 26 | Chinoporos Constantine | other | 0 |
| Jul 16, 26 | Richton Kathleen P. | other | 0 |
| Jul 16, 26 | Richton Kathleen P. | other | 0 |
| Jul 16, 26 | Richton Kathleen P. | other | 0 |
| Jul 16, 26 | Richton Kathleen P. | other | 0 |
| Jun 16, 26 | Astley-Sparke Philip | other | 31,000 |
| Jun 16, 26 | BRUNK GERALD A | other | 31,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ENGN coverage
Recent articles, reports, and earnings notes.
No research on ENGN yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ENGN report →enGene Therapeutics Inc. (ENGN) Presents at UBS Global Biopharma Conference 2026 Transcript
seekingalpha.com · Nov 16
enGene Therapeutics Inc. (ENGN) Discusses Updated LEGEND Data and Regulatory Path for Detalimogene Transcript
seekingalpha.com · Nov 11
enGene to Initiate a BLA Submission for Detalimogene by Year End and Reports New Data from LEGEND Trial Pivotal Cohort 1 in BCG-Unresponsive NMIBC
businesswire.com · Nov 11
enGene Appoints Key Executives in Anticipation of Upcoming Regulatory and Commercial Milestones
businesswire.com · Nov 11
enGene to Participate in Upcoming Investor Conferences
businesswire.com · Nov 6
enGene Holdings Inc. (NASDAQ:ENGN) Stock Has Average Price Target of $11.05 According to Brokerages
defenseworld.net · Nov 6
enGene Highlights Surfactant-Enhanced Bladder Cancer Therapy Data and 2027 Update Path
marketbeat.com · Oct 16
enGene Therapeutics Inc. (ENGN) Discusses Preclinical Data and Clinical Case Studies on Incorporating Surfactant Bladder Rinse into Treatment Transcript
seekingalpha.com · Oct 15
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.